Literature DB >> 26462809

Combined prognostic value of absolute lymphocyte/monocyte ratio in peripheral blood and interim PET/CT results in Hodgkin lymphoma.

Zsofia Simon, S Barna, Z Miltenyi, K Husi, F Magyari, A Jona, I Garai, Z Nagy, G Ujj, L Szerafin, A Illes.   

Abstract

Decreased absolute lymphocyte/monocyte ratio (LMR) in peripheral blood has been reported as an unfavorable prognostic marker in Hodgkin lymphoma. We aimed to investigate whether combining LMR and interim PET/CT scan result (PET2) confers stronger prognostic value than PET2 alone. 121 HL patients were investigated. LMR was calculated from a blood sample taken at the time of diagnosis. PET2 was carried out after the second chemotherapy cycle. Survival was calculated using the Kaplan-Meier method and significance was determined by log-rank test. Effect of variants on survival results was examined using univariate and multivariate analyses. Best LMR cut-off value was determined by receiver operating characteristic (ROC) curve. Best LMR cut-off value was 2.11 in the case of our patients (LMR > 2.11: favorable, LMR ≤ 2.11: unfavorable). Overall and progression-free survivals (OS/PFS) were significantly worse both in lower LMR (≤ 2.11) (OS: P = 0.041, PFS: P = 0.044) and PET2 positive groups (OS: P < 0.001, PFS: P < 0.001). In PET2 positive patient group (n = 32) the low LMR result meant a significantly worse OS (0.030) and PFS (0.001). Both LMR and PET2 proved to be independent prognostic factors on multivariate analysis, and strengthened each other's effect.

Entities:  

Mesh:

Year:  2016        PMID: 26462809     DOI: 10.1007/s12185-015-1884-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

1.  Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.

Authors:  Luis F Porrata; Kay Ristow; Joseph P Colgan; Thomas M Habermann; Thomas E Witzig; David J Inwards; Stephen M Ansell; Ivana N Micallef; Patrick B Johnston; Grzegorz S Nowakowski; Carrie Thompson; Svetomir N Markovic
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

2.  Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma.

Authors:  Sally F Barrington; Wendi Qian; Edward J Somer; Antonella Franceschetto; Bruno Bagni; Eva Brun; Helén Almquist; Annika Loft; Liselotte Højgaard; Massimo Federico; Andrea Gallamini; Paul Smith; Peter Johnson; John Radford; Michael J O'Doherty
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-27       Impact factor: 9.236

3.  The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Authors:  Andrea Gallamini; Sally F Barrington; Alberto Biggi; Stephane Chauvie; Lale Kostakoglu; Michele Gregianin; Michel Meignan; George N Mikhaeel; Annika Loft; Jan M Zaucha; John F Seymour; Michael S Hofman; Luigi Rigacci; Alessandro Pulsoni; Morton Coleman; Eldad J Dann; Livio Trentin; Olivier Casasnovas; Chiara Rusconi; Pauline Brice; Silvia Bolis; Simonetta Viviani; Flavia Salvi; Stefano Luminari; Martin Hutchings
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  The prognostic relevance of tumor associated macrophages in advanced stage classical Hodgkin lymphoma.

Authors:  Ljubomir R Jakovic; Biljana S Mihaljevic; Maja D Perunicic Jovanovic; Andrija D Bogdanovic; Bosko M Andjelic; Vladimir Z Bumbasirevic
Journal:  Leuk Lymphoma       Date:  2011-06-12

6.  Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.

Authors:  Kimberley Jones; Frank Vari; Colm Keane; Pauline Crooks; Jamie P Nourse; Louise A Seymour; David Gottlieb; David Ritchie; Devinder Gill; Maher K Gandhi
Journal:  Clin Cancer Res       Date:  2012-12-05       Impact factor: 12.531

7.  Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma.

Authors:  Maike Sauer; Annette Plütschow; Ron D Jachimowicz; Dominik Kleefisch; Katrin S Reiners; Sabine Ponader; Andreas Engert; Elke Pogge von Strandmann
Journal:  Am J Hematol       Date:  2012-12-08       Impact factor: 10.047

8.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study.

Authors:  Andrea Gallamini; Martin Hutchings; Luigi Rigacci; Lena Specht; Francesco Merli; Mads Hansen; Caterina Patti; Annika Loft; Francesco Di Raimondo; Francesco D'Amore; Alberto Biggi; Umberto Vitolo; Caterina Stelitano; Rosario Sancetta; Livio Trentin; Stefano Luminari; Emilio Iannitto; Simonetta Viviani; Ivana Pierri; Alessandro Levis
Journal:  J Clin Oncol       Date:  2007-07-23       Impact factor: 44.544

9.  The ratio of the absolute lymphocyte count to the absolute monocyte count is associated with prognosis in Hodgkin's lymphoma: correlation with tumor-associated macrophages.

Authors:  Young Wha Koh; Hyo Jeong Kang; Chansik Park; Dok Hyun Yoon; Shin Kim; Cheolwon Suh; Heounjeong Go; Ji Eun Kim; Chul-Woo Kim; Jooryung Huh
Journal:  Oncologist       Date:  2012-05-15

Review 10.  State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Front Oncol       Date:  2013-09-04       Impact factor: 6.244

View more
  4 in total

1.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2019-09-16

2.  Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.

Authors:  Angela Aldin; Lisa Umlauff; Lise J Estcourt; Gary Collins; Karel Gm Moons; Andreas Engert; Carsten Kobe; Bastian von Tresckow; Madhuri Haque; Farid Foroutan; Nina Kreuzberger; Marialena Trivella; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2020-01-13

3.  Clinical and biological prognostic factors in follicular lymphoma patients.

Authors:  Ádám Jóna; Anna Kenyeres; Sándor Barna; Árpád Illés; Zsófia Simon
Journal:  PLoS One       Date:  2022-08-04       Impact factor: 3.752

4.  The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PET-2-adapted HD0607 trial.

Authors:  Alessandra Romano; Chiara Pavoni; Francesco Di Raimondo; Corrado Tarella; Simonetta Viviani; Andrea Rossi; Caterina Patti; Marco Picardi; Maria Cantonetti; Giorgio La Nasa; Livio Trentin; Silvia Bolis; Valerio Zoli; Paolo Gavarotti; Paolo Corradini; Michele Cimminiello; Corrado Schiavotto; Guido Parvis; Roberta Zanotti; Guido Gini; Andrés J M Ferreri; Piera Viero; Stephane Chauvie; Alberto Biggi; Alessandro Massimo Gianni; Andrea Gallamini; Alessandro Rambaldi
Journal:  Cancer Med       Date:  2020-11-06       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.